NCT02508922

Brief Summary

To build on a recent case study and open label trial, the investigators want to find out if vitamin D supplementation can influence behavioural and core symptoms of autism.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 24, 2015

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 27, 2015

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2015

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2016

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2016

Completed
Last Updated

October 25, 2016

Status Verified

October 1, 2016

Enrollment Period

9 months

First QC Date

July 24, 2015

Last Update Submit

October 24, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in stereotypic behaviour from the aberrant behaviour checklist

    A subscale derived from the validated aberrant behaviour checklist

    Day 1 and day 140

Secondary Outcomes (10)

  • Change from baseline in serum 25-hydroxyvitamin D levels

    Day 1 and day 140

  • Change from baseline in serum calcium levels, corrected for albumin

    Day 1 and day 140

  • Change from baseline in aberrant behaviour checklist

    Day 1 and day 140

  • Change from baseline in cytokines

    Day 1 and day 140

  • Change from baseline in autoimmune markers

    Day 1 and day 140

  • +5 more secondary outcomes

Study Arms (2)

Vitamin D3

EXPERIMENTAL

2000iu vitamin D will be taken daily for 20 weeks.

Dietary Supplement: Vitamin D3

Placebo

PLACEBO COMPARATOR

Matching placebo drops will be taken daily for 20 weeks

Dietary Supplement: Placebo

Interventions

Vitamin D3DIETARY_SUPPLEMENT

2,000iu vitamin D drops will be taken daily for 20 weeks

Also known as: cholecalciferol
Vitamin D3
PlaceboDIETARY_SUPPLEMENT

Matching placebo drops will be taken daily for 20 weeks

Placebo

Eligibility Criteria

Age3 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Positive autism diagnostic observation schedule
  • Stable medication regimen
  • Tolerate phlebotomy

You may not qualify if:

  • Unstable or very severe autism
  • Epilepsy
  • Renal/liver/gastrointestinal disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

National Children's Hopsital

Dublin, Dublin, D24, Ireland

Location

Linn Dara and BeechPark

Dublin, D10, Ireland

Location

Trinity College Dublin

Dublin, D2, Ireland

Location

Related Publications (11)

  • Cannell JJ. Autism and vitamin D. Med Hypotheses. 2008;70(4):750-9. doi: 10.1016/j.mehy.2007.08.016. Epub 2007 Oct 24.

    PMID: 17920208BACKGROUND
  • Eyles DW. Vitamin D and autism: does skin colour modify risk? Acta Paediatr. 2010 May;99(5):645-647. doi: 10.1111/j.1651-2227.2010.01797.x. Epub 2010 Mar 8. No abstract available.

    PMID: 20219042BACKGROUND
  • Becker KG. Autism, immune dysfunction and Vitamin D. Acta Psychiatr Scand. 2011 Jul;124(1):74; author reply 74-5. doi: 10.1111/j.1600-0447.2011.01688.x. Epub 2011 Mar 13. No abstract available.

    PMID: 21395563BACKGROUND
  • Kocovska E, Fernell E, Billstedt E, Minnis H, Gillberg C. Vitamin D and autism: clinical review. Res Dev Disabil. 2012 Sep-Oct;33(5):1541-50. doi: 10.1016/j.ridd.2012.02.015. Epub 2012 Apr 21.

    PMID: 22522213BACKGROUND
  • Mostafa GA, Al-Ayadhi LY. Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. J Neuroinflammation. 2012 Aug 17;9:201. doi: 10.1186/1742-2094-9-201.

    PMID: 22898564BACKGROUND
  • Cannell JJ. Autism, will vitamin D treat core symptoms? Med Hypotheses. 2013 Aug;81(2):195-8. doi: 10.1016/j.mehy.2013.05.004. Epub 2013 May 29.

    PMID: 23725905BACKGROUND
  • Cannell JJ, Grant WB. What is the role of vitamin D in autism? Dermatoendocrinol. 2013 Jan 1;5(1):199-204. doi: 10.4161/derm.24356.

    PMID: 24494055BACKGROUND
  • Patrick RP, Ames BN. Vitamin D hormone regulates serotonin synthesis. Part 1: relevance for autism. FASEB J. 2014 Jun;28(6):2398-413. doi: 10.1096/fj.13-246546. Epub 2014 Feb 20.

    PMID: 24558199BACKGROUND
  • Jia F, Wang B, Shan L, Xu Z, Staal WG, Du L. Core symptoms of autism improved after vitamin D supplementation. Pediatrics. 2015 Jan;135(1):e196-8. doi: 10.1542/peds.2014-2121. Epub 2014 Dec 15.

    PMID: 25511123BACKGROUND
  • Saad K, Abdel-Rahman AA, Elserogy YM, Al-Atram AA, Cannell JJ, Bjorklund G, Abdel-Reheim MK, Othman HA, El-Houfey AA, Abd El-Aziz NH, Abd El-Baseer KA, Ahmed AE, Ali AM. Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children. Nutr Neurosci. 2016 Oct;19(8):346-351. doi: 10.1179/1476830515Y.0000000019. Epub 2015 Apr 15.

    PMID: 25876214BACKGROUND
  • Kerley CP, Power C, Gallagher L, Coghlan D. Lack of effect of vitamin D3 supplementation in autism: a 20-week, placebo-controlled RCT. Arch Dis Child. 2017 Nov;102(11):1030-1036. doi: 10.1136/archdischild-2017-312783. Epub 2017 Jun 16.

MeSH Terms

Conditions

Autistic Disorder

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

Autism Spectrum DisorderChild Development Disorders, PervasiveNeurodevelopmental DisordersMental Disorders

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dietitian and Nutrition Scientist

Study Record Dates

First Submitted

July 24, 2015

First Posted

July 27, 2015

Study Start

September 1, 2015

Primary Completion

June 1, 2016

Study Completion

July 1, 2016

Last Updated

October 25, 2016

Record last verified: 2016-10

Locations